RudaCure Inc., which develops treatments for intractable diseases, was announced as a final selection for the Ministry of SMEs and Startups' Startup Leap Forward Package Program on April 28th.
This program funding is expected to be utilized for research on commercializing the peptide drug for pain treatment currently under development, as well as for external promotion activities.
This is expected to serve as the starting point for RudaCure Inc., which is entering its fifth year since founding, to take a leap forward.
Starting with this program, RudaCure has completed all preparations for clinical trials of the dry eye disease treatment and ocular mucosal damage treatment currently under development, and will begin full-scale reagent production for clinical trials starting next month.
Additionally, a busy schedule of commercialization activities is planned, including BIO KOREA in May, the presentation of RCI002 preclinical results for chemotherapy-induced pain treatment at ASCO in June, and attendance at BIO USA.
At BIO KOREA, meetings are scheduled with companies showing potential as multinational partners for RCI002,
and at BIO USA, collaboration with multinational partners interested in veterinary drug development is also anticipated, offering a chance to witness the company's rapid growth.
